Table 2.
Baseline characteristics for patients in the development and validation cohorts according to non-achievement of remission
| q | Nordic development cohort (N = 427) | ReACCh-Out validation cohort (N = 506) | ||
|---|---|---|---|---|
| Remission (n = 181) | Non-remission (n = 246) | Remission (n = 98) | Non-remission (n = 408) | |
| Characteristics | ||||
| Age at onset, years | 5.9 (2.5, 10.0)* | 5.2 (2.5, 9.5) | 8.0 (3.6, 11.5) | 7.2 (2.6, 11.1) |
| Female, n (%) | 115 (63.5) | 169 (68.7) | 62 (63.3) | 285 (70.4) |
| Onset to enrolment, months | 7 (6, 8) | 6.5 (6, 8) | 3.9 (2.4, 6.0) | 5.1 (2.7, 9.7) |
| JIA category, n (%)** | ||||
| Oligoarthritis | 107 (59.1) | 111 (45.1) | 55 (56.1) | 137 (33.6) |
| RF-neg. polyarthritis | 25 (13.8) | 68 (27.6) | 4 (4.1) | 113 (27.7) |
| RF-pos. polyarthritis | 1 (0.6) | 3 (1.2) | 0 (0.0) | 17 (4.2) |
| Systemic | 15 (8.3) | 2 (0.8) | 13 (13.3) | 28 (6.9) |
| Enthesitis-related | 11 (6.1) | 23 (9.3) | 8 (8.2) | 50 (12.3) |
| Psoriatic | 3 (1.7) | 3 (1.2) | 8 (8.2) | 20 (4.9) |
| Undifferentiated | 19 (10.5) | 36 (14.6) | 10 (10.2) | 43 (10.5) |
| Assessments and laboratory tests | ||||
| Active joints, n (%) | ||||
| Cervical arthritis | 13 (7.2) | 25 (10.2) | 0 (0.0) | 26 (7.0) |
| Finger arthritis | 40 (22.1) | 94 (38.2) | 16 (19.3) | 167 (44.7) |
| Ankle arthritis | 65 (35.9) | 129 (52.4) | 17 (20.5) | 186 (49.7) |
| Hip arthritis | 24 (13.3) | 38 (15.4) | 7 (8.4) | 50 (13.4) |
| Active joint count*** | 2 (1, 4) | 4 (2, 7) | 1 (1, 2) | 3 (1, 9) |
| Physician global assessment | 0.8 (0.0, 1.3) | 2.0 (1.0, 3.8) | 1.9 (1.0, 3.2) | 3.8 (2.0, 6.0) |
| Parent global assessment | 0.6 (0.0, 2.0) | 1.7 (0.5, 3.5) | 0.7 (0.2, 2.4) | 2.3 (0.7, 4.9) |
| Pain | 0.4 (0.0, 3.0) | 2.3 (0.5, 4.2) | 1.0 (0.2, 3.0) | 3.9 (1.0, 6.1) |
| CHAQ DI | 0.1 (0.0, 0.6) | 0.5 (0.0, 1.1) | 0.1 (0.0, 0.5) | 0.5 (0.1, 1.1) |
| Stiffness > 15 min (%) | 30 (16.6) | 90 (36.6) | 45 (55.6) | 184 (65.0) |
| ESR**** | 11.5 (6, 20) | 17.5 (10, 31) | 20 (9, 34) | 21 (9, 40) |
| CRP**** | 0.0 (0, 0) | 0.0 (0, 15) | 2.0 (0.2, 10) | 3.0 (0.3, 17) |
| ANA | 37 (20.4) | 76 (30.9) | 49 (50.0) | 182 (50.7) |
| RF | 5 (2.8) | 5 (2.0) | 5 (5.1) | 23 (6.4) |
| HLA B27 | 22 (12.2) | 60 (24.4) | 5 (5.1) | 36 (10.0) |
| Treatment by first study visit (%) | ||||
| NSAIDs | 152 (84.0) | 215 (87.4) | 88 (89.8) | 390 (95.6) |
| Joint injections | 84 (46.4) | 152 (61.8) | 24 (24.5) | 88 (21.6) |
| DMARDs | 20 (11.0) | 71 (28.9) | 9 (9.2) | 137 (33.6) |
| Biologics | 0 | 0 | 1 (1) | 1 (0.2) |
*Numbers are median (25th centile, 75th centile) or number of patients (%)
**Patients with systemic JIA were excluded from the Nordic prediction model development study. They are included in the validation cohort and in this table
***The Nordic development cohort used the cumulative active joint count within 6 months of disease onset, and the ReACCh-Out validation cohort used the active joint count at baseline
****Erythrocyte sedimentation rate measurements were available for 322 of 427 patients (75.4%) in the Nordic cohort and for 458 of 506 patients (90.5%) in the ReACCh-Out cohort. C-reactive protein measurements were available for 345 of 427 patients (80.8%) in the Nordic cohort and 404 of 506 patients (79.8%) in the ReACCh-Out cohort